Ulcerative colitis (UC) and Crohn’s disease (CD) are two inflammatory bowel diseases that are characterised by chronic inflammation in the gastrointestinal (GI) tract.7,8 Together, they affect an estimated 260,000 people in the UK, typically during early adulthood or between the ages of 55 and 65 years.2,3 While there is no known cure, medical treatments, lifestyle interventions and surgery can greatly reduce symptoms and bring about remission.2 3 7 8LEARN MORE
Entyvio is the only first gut selective biologic approved for the treatment of adults with moderately to severely active UC or CD who have experienced an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist.1LEARN MORE
Takeda Pharmaceutical Company Limited has a long history in the research and development, manufacturing, sales and marketing, and import/export of pharmaceutical products. The corporate mission to “strive towards better health for people worldwide through leading innovation in medicine” has led to the development of several state-of-the-art medicines, including Entyvio for UC and CD.LEARN MORE
If you have been prescribed Entyvio and get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible side effects not listed within this website or in the Patient Information Leaflet.
Adverse events should be reported. In the United Kingdom, reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Takeda on 01628 537900 or e-mail DSO-UK@takeda.com